Moderna gets Autolus targeting tech via licensing deal; Atai reports PhI data for kratom-based therapy

2022-10-12

信使RNA

A year after Autolus Therapeutics got itself a partner in Moderna via a licensing deal, Moderna is exercising its option to acquire the biotech’s proprietary binders. The London-based Autolus revealed the option Wednesday morning, saying that the mRNA giant has exercised its option to in-license for an undisclosed I/O target. The original agreement between the two companies was reached back in August 2021, which gave Moderna the option to license Autolus’ tech for up to four immune-oncology targets. Autolus now has received the exercise payment and remains up to receiving milestone payments and royalties. Shares of $AUTL initially went up 15% after the announcement. Autolus CSO Martin Pule said via a statement that the collaboration with Moderna has been productive, calling it good to see the partnership move forward. The Peter Thiel-backed startup atai is reporting optimistic data for its OUD (opioid use disorder) candidate. The biotech reported that drug candidate KUR-101, an oral formulation of a deuterated key component of the kratom plant called mitragynine, showed safety data and that it was well-tolerated in patients. In the single ascending dose portion of the trial, no severe or serious adverse events were reported. However, efficacy data compared to standard-of-care drugs such as naltrexone and methadone is still in the clinic. Those data are expected by end of the year, which would compare a single dose of KUR-101 to a dose of oxycodone or placebo. CEO Chad Beyer of atai subsidiary Kures, which is leading the KUR-101 program, said that it’s pleased with the results of the trial.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构